NewswireTODAY - /newswire/ - Mainz, Rhineland-Palatinate, Germany, 2026/01/15 - SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, continues its collaboration with SHL Medical and pre-validates the ISO-standardized polymer cartridge with SHL Medical’s large-volume autoinjector platform - SCHOTT-Pharma.com.

• SCHOTT TOPPAC® cartridge is the first sterile polymer cartridge platform verified for compatibility with SHL Medical’s Maggie® autoinjector platform;
• It’s the industry’s first ISO-standardized ready-to-use (RTU) polymer cartridge designed for the administration of highly sensitive biologics in large volumes;
• Further compatibility studies with medical devices are underway, paving the way for broader integrated drug delivery solutions.

The SCHOTT TOPPAC® polymer cartridge is the first in SCHOTT Pharma’s polymer product portfolio to meet both ISO dimensions and the global RTU standard, SCHOTT iQ®. Polymer solutions come into play when medications have special requirements, such as low silicone levels or deep-temperature storage, for example. The polymer cartridges are suitable for safely storing and administering highly sensitive biologics, including cell and gene therapies, biosimilars, and emergency medications.

“Thanks to our collaboration with SHL Medical, we’ve taken a big step forward in offering a complete solution to pharma companies”, says Andreas Reisse, CEO of SCHOTT Pharma.

The system developed by SCHOTT Pharma and pre-validated for compatibility with SHL Medical (shl-medical.com) will be showcased at Pharmapack Paris, January 21-22 (hall 4, booth G38).

Pre-validated system

SCHOTT Pharma and SHL Medical conducted compatibility studies that assessed both dimensional as well as functional fit of the SCHOTT TOPPAC® polymer cartridge with Maggie® autoinjector platforms. The joint assessment confirmed the full system compatibility. This includes the 3 ml SCHOTT TOPPAC® cartridge with Maggie® 3.0 ml and the 5 ml SCHOTT TOPPAC® cartridge with Maggie® 5.0 ml autoinjector.

This milestone enables access to a pre-validated and de-risked solution for the safe and convenient administration of large-volume medications at home, supporting self‑injection for a wide range of therapies.

As part of the SCHOTT iQ® platform, the polymer cartridge is delivered in an industry-standard nest-and-tub configuration, streamlining fill-and-finish processes and helping to accelerate time to market for pharmaceutical companies.

In addition to the polymer option, SCHOTT Pharma’s 3 ml and 5 ml cartriQ® glass cartridges are also compatible with the Maggie® 3.0 ml and 5.0 ml autoinjectors, providing pharmaceutical companies with options for material choice tailored to the specific needs of each therapy and patient population.

Expanding compatibility with further medical devices

Building on this achievement, SCHOTT Pharma and SHL Medical are expanding their collaboration with future studies assessing the compatibility of the SCHOTT TOPPAC® polymer cartridge with SHL Medical’s pen systems. SCHOTT Pharma is also exploring opportunities to extend compatibility to additional medical devices in the future.

“Our strong partnership with SCHOTT Pharma has been instrumental in driving both productivity and innovation. By working hand in hand, we’re developing solutions that meet the evolving needs of patients and industry stakeholders,” emphasizes Markus Puusepp, Chief Growth Officer at SHL Medical. “We are excited to continue this close collaboration, leveraging the SCHOTT TOPPAC® cartridge alongside our advanced injection device systems to deliver even greater value.”

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma (schott-pharma.com) designs containment solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 30,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,800 people from over 65 nations works at SCHOTT Pharma to contribute to global health. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 986 million in the fiscal year 2025. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment.

Agency / Source: SCHOTT North America

Availability: All Regions (Including Int'l)

Traffic Booster: [/] Quick NewswireToday Visibility Checker

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]